Advertisement

Infection

pp 1–9 | Cite as

Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016

  • Melanie StecherEmail author
  • Philipp Schommers
  • Daniel Schmidt
  • Christian Kollan
  • Barbara Gunsenheimer-Bartmeyer
  • Clara Lehmann
  • Martin Platten
  • Gerd Fätkenheuer
  • Jörg Janne VehreschildEmail author
  • ClinSurv Study Group
Original Paper

Abstract

Purpose

The aim of the study was to assess guideline adherence to combined antiretroviral therapy (ART) in the German ClinSurv HIV Cohort and the real-life impact of the Strategic Timing of Antiretroviral Therapy (START) study, to identify patients not treated as recommended by new guidelines.

Methods

We used data from the multicenter ClinSurv cohort of the Robert-Koch-Institute (RKI) between 1999 and 2016. Inclusion criteria were people living with HIV/AIDS, ≥ 18 years of age and cART naïve at the first visit (FV). Adherence was defined as starting cART within 6 months of crossing the CD4+ T cell threshold as suggested by the German-Austrian treatment guidelines. Logistic regression was used to identify factors associated with non-adherence.

Results

11,817 patients met the inclusion criteria. We observed an overall adherence rate of 60%, in patients with treatment indication who started cART timely between 2002 and 2015. Adherence rate increased constantly, demonstrating a potential increase in patients, with treatment indication, starting cART within 6 months of presentation from 55% in 2008 to 94% in 2015. Patients reporting injection drug use (OR 2.18, 95% CI 1.70–2.95) and patients between 18 years and 39 years of age at the time of their first visit (OR 2.89, 95% CI 1.35–6.18) were identified as risk groups associated with non-adherence.

Conclusion

The majority of patients below the CD4+ T cell count threshold of applicable guidelines initiated treatment within 6 months. We observed a slowly diminishing proportion of patients not starting cART timely. Delayed treatment was more frequent in patients reporting injection drug use.

Keywords

HIV Antiretroviral therapy START Treatment guidelines Adherence 

Notes

Acknowledgements

This study was funded by the German Center for Infection Research. Initial results of this study were presented at the ‘21st International Workshop on HIV and Hepatitis Observational Databases’ in Lisbon, Portugal 2016, Abstract no: 109.

Author contributions

JV and MS designed the study, analyzed and interpreted the data. MS drafted the primary draft of the manuscript. BG, CK and DS provided data, and contributed critically important ideas on how to interpret the data. PS, BG, CK, DS, MP, CL and GF revised the manuscript critically for important intellectual content. All authors approved the final version of the manuscript.

Compliance with ethical standards

Conflict of interest

This study is a project within the TP-HIV by the German Centre for Infection Research (DZIF) (NCT02149004). We declare that all authors have no conflicts of interest.

Supplementary material

15010_2018_1248_MOESM1_ESM.docx (24 kb)
Supplementary material 1 (DOCX 24 KB)

References

  1. 1.
    Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–223.CrossRefPubMedGoogle Scholar
  2. 2.
    Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–96.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    The Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–e56.CrossRefGoogle Scholar
  4. 4.
    Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11–9.CrossRefPubMedGoogle Scholar
  5. 5.
    May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. Br Med J. 2011;343:11.Google Scholar
  6. 6.
    UNAIDS. Fact sheet—latest statistics on the status of the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed Feb 2018.
  7. 7.
    UNAIDS. 90-90-90—an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations; 2014.Google Scholar
  8. 8.
    Camacho R, Teofilo E. Antiretroviral therapy in treatment-naive patients with HIV infection. Curr Opin HIV AIDS. 2011;6:3–11.CrossRefGoogle Scholar
  9. 9.
    Brouwer ES, Napravnik S, Eron JJ Jr, et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology. 2014;25:406–17.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281–90.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hofstra LM, Sauvageot N, Albert J, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016;62:655–63.CrossRefPubMedGoogle Scholar
  12. 12.
    Phillips AN, Cambiano V, Miners A, et al. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. Aids. 2015;29:1855–62.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Stoll M, Claes C, Schulte E, Korner T, von der Schulenburg JM, Schmidt R. [Public health economic aspects of antiretroviral therapy. Can we afford to do less?]. MMW Fortschr Med. 2000;142:45–9.PubMedGoogle Scholar
  14. 14.
    Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Def Syndrom. 1999;2006; 43:451–7.CrossRefGoogle Scholar
  16. 16.
    Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.CrossRefPubMedGoogle Scholar
  17. 17.
    The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808–22.CrossRefGoogle Scholar
  18. 18.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. US-Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed January 2018.
  19. 19.
    Waters L, Ahmed N, Angus B, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). http://www.bhiva.org/documents/Guidelines/Treatment/2016/treatment-guidelines-2016-interim-update.pdf. Accessed Oct 2017.
  20. 20.
    EACS. European Guidelines for treatment of HIV-positive adults in Europe 8.0. http://www.eacsociety.org/files/guidelines_8.0-english-revised_20160610.pdf. Accessed Oct 017.
  21. 21.
    Deutsche AIDS-Gesellschaft, Österreichische. AIDS-Gesellschaft. Deutsch -Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. http://www.daignet.de/site-content/hiv-therapie/leitlinien-1. Accessed Oct 2017.
  22. 22.
    Deutsche AIDSG. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, 2014.Google Scholar
  23. 23.
    Deutsche AIDS-Gesellschaft, Österreichische. AIDS-Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, 2012.Google Scholar
  24. 24.
    Deutsche AIDS-Gesellschaft, Österreichische. AIDS-Gesellschaft. Deutsch -Österreichische Leitlinien zur Therapie der HIV-Infektion 2010, 2010.Google Scholar
  25. 25.
    Batzing-Feigenbaum J, Kollan C, Kuhne A, Matysiak-Klose D, Gunsenheimer-Bartmeyer B, Hamouda O. Cohort profile: the German ClinSurv HIV project–a multicentre open clinical cohort study supplementing national HIV surveillance. HIV Med. 2011;12:269–78.CrossRefPubMedGoogle Scholar
  26. 26.
    Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. J Acquir Immune Def Syndrom Hum Retrovirol. 1999;20:220–7.CrossRefGoogle Scholar
  27. 27.
    Deutsche AIDS-Gesellschaft. Österreichische AIDS-Gesellschaft. Deutsch -Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion 2002. Dtsch Med Wochenschr 2003; (128): S7-S18.Google Scholar
  28. 28.
    Deutsche AIDS-Gesellschaft, Österreichische. AIDS-Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion 2008. 2008.Google Scholar
  29. 29.
    Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34:502–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Centers for Disease Control and Prevention. revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recommend Rep Morbid Mortal Week Rep Recommend Rep 1992. 1993;41:1–19.Google Scholar
  31. 31.
    Schmidt D, Kollan C, Stoll M, et al. From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany. BMC Public Health. 2015;15:252.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    INSIGHT START Study Group. Strategic timing of antiretroviral treatment (START) study primary results. In: 8th IAS conference on HIV pathogenesis treatment and prevention. Vancouver, Canada, 2015.Google Scholar
  33. 33.
    Danel C, Moh R, Gabillard D, et al. Early ART and IPT in HIV-infected African adults with high CD4 Count (Temprano Trial). Conference on retroviruses and opportunistic infections. Seattle, WA, USA, 2015.Google Scholar
  34. 34.
    Stecher M, Chaillon A, Eis-Hubinger AM, et al. Pre treatment HIV-1 drug resistance in transmission clusters of the Cologne-Bonn Region, Germany. Clin Microbiol Infect 2018.Google Scholar
  35. 35.
    Azar P, Wood E, Nguyen P, et al. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. BMC Infect Dis. 2015;15:193.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Def Syndrom 1999;2007; 46:64–71.CrossRefGoogle Scholar
  37. 37.
    Bolsewicz K, Debattista J, Vallely A, Whittaker A, Fitzgerald L. Factors associated with antiretroviral treatment uptake and adherence: a review. Perspectives from Australia, Canada, and the United Kingdom. AIDS Care. 2015;27:1429–38.CrossRefPubMedGoogle Scholar
  38. 38.
    Rebolledo P, Kourbatova E, Rothenberg R, del Rio C. Factors associated with utilization of HAART amongst hard-to-reach HIV-infected individuals in Atlanta, Georgia. J AIDS HIV Res (Online). 2011;3:63–70.Google Scholar
  39. 39.
    Robert-Koch-Institut. Epidemiologisches Bulletin 45, page 476–483. http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/45_15.pdf?__blob=publicationFile. Accessed Jun 2017.
  40. 40.
    Vourli G, Pharris A, Cazein F, et al. Assessing the representativeness of European HIV cohort participants as compared to HIV surveillance data. In: Control ECfDPa. HepHIV. Malta, 2017.Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Melanie Stecher
    • 1
    • 2
    Email author
  • Philipp Schommers
    • 1
    • 2
  • Daniel Schmidt
    • 3
    • 4
  • Christian Kollan
    • 3
  • Barbara Gunsenheimer-Bartmeyer
    • 3
  • Clara Lehmann
    • 1
    • 2
  • Martin Platten
    • 1
  • Gerd Fätkenheuer
    • 1
    • 2
  • Jörg Janne Vehreschild
    • 1
    • 2
    Email author
  • ClinSurv Study Group
  1. 1.Department I for Internal MedicineUniversity Hospital of CologneCologneGermany
  2. 2.Partner Site Cologne-BonnGerman Center for Infection Research (DZIF)CologneGermany
  3. 3.Department of Infectious Disease EpidemiologyRobert Koch InstituteBerlinGermany
  4. 4.Charité – University Medicine BerlinBerlinGermany

Personalised recommendations